In the world of bioanalytical contract research organizations (CROs), the management of project backlogs plays a pivotal role in both day-to-day operations and long-term success. Our latest article delves into how backlog is a critical factor during mergers and acquisitions (M&A) in the bioanalytical CRO space.

In this article we examine the dual nature of backlog — its potential to indicate strong future growth as well as the risks it can pose if not properly managed. A backlog can serve as a valuable asset, signaling high demand and future revenue, especially when it reflects large, stable clients or promising therapeutic areas. However, a backlog that’s growing too quickly or is poorly managed can reveal operational inefficiencies, resource strain and potential client dissatisfaction.

Key questions around backlog data — such as demand, client concentration, project dependencies and revenue forecasts — can provide deep insights during the due diligence process. This article offers a comprehensive guide for investors and CROs to better understand and manage backlogs, ensuring they’re positioned for sustainable growth and success in a competitive market.